NYSE:PKI (USA) Also trade in: Germany UK

PerkinElmer Inc

$ 93.38 0.44 (0.47%)
Volume: 582,631 Avg Vol (1m): 1,022,762
Market Cap $: 10.36 Bil Enterprise Value $: 12.09 Bil
P/E (TTM): 42.05 P/B: 3.95
Earnings Power Value 16.72
Net Current Asset Value -19.77
Tangible Book -13.19
Projected FCF 43.98
Median P/S Value 51.4
Graham Number 0
Peter Lynch Value 25.91
DCF (FCF Based) 26.61
DCF (Earnings Based) 58.38
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.07
Cash-To-Debt ranked lower than
92.72% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
PKI: 0.07
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.07, Med: 0.35, Max: 2.06
Current: 0.07
0.07
2.06
Equity-to-Asset 0.43
Equity-to-Asset ranked lower than
77.82% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
PKI: 0.43
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.24, Med: 0.52, Max: 0.63
Current: 0.43
0.24
0.63
Debt-to-Equity 0.71
Debt-to-Equity ranked lower than
75.61% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
PKI: 0.71
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.1, Med: 0.38, Max: 1.61
Current: 0.71
0.1
1.61
Debt-to-EBITDA 3.60
Debt-to-EBITDA ranked lower than
81.03% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
PKI: 3.6
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 1.57, Med: 3.31, Max: 4.72
Current: 3.6
1.57
4.72
Interest Coverage 5.36
Interest Coverage ranked lower than
72.39% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
PKI: 5.36
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 4.34, Med: 6.1, Max: 11.11
Current: 5.36
4.34
11.11
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.14
DISTRESS
GREY
SAFE
Beneish M-Score -2.47
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 7.44%
WACC 9.58%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 12.56
Operating Margin ranked higher than
76.45% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
PKI: 12.56
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 5.61, Med: 11.22, Max: 14.17
Current: 12.56
5.61
14.17
Net Margin % 8.89
Net Margin ranked higher than
85.48% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
PKI: 8.89
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 0.4, Med: 8.16, Max: 22.98
Current: 8.89
0.4
22.98
ROE % 9.61
ROE ranked higher than
77.27% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
PKI: 9.61
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 0.41, Med: 8.93, Max: 22
Current: 9.61
0.41
22
ROA % 4.12
ROA ranked higher than
77.48% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
PKI: 4.12
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 0.22, Med: 4.1, Max: 12.48
Current: 4.12
0.22
12.48
ROC (Joel Greenblatt) % 50.51
ROC (Joel Greenblatt) ranked higher than
91.12% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
PKI: 50.51
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 26.99, Med: 51.1, Max: 76.53
Current: 50.51
26.99
76.53
3-Year Total Revenue Growth Rate 9.70
3-Year Revenue Growth Rate ranked lower than
54.95% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
PKI: 10.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -21, Med: 0.7, Max: 20.5
Current: 10.3
-21
20.5
3-Year Total EBITDA Growth Rate 12.80
3-Year EBITDA Growth Rate ranked higher than
65.73% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
PKI: 13.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -15.5, Med: 5.2, Max: 35.4
Current: 13.4
-15.5
35.4
3-Year EPS w/o NRI Growth Rate 8.40
3-Year EPS w/o NRI Growth Rate ranked lower than
55.21% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
PKI: 8.4
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 5.8, Max: 384.9
Current: 8.4
0
384.9

» PKI's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:PKI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 334516    SIC : 8071
Compare XPAR:BIM NYSE:BIO NYSE:QGEN NAS:DXCM XPAR:ERF NAS:ICLR XTER:SRT NAS:GH NAS:EXAS NAS:BRKR NYSE:CRL NYSE:DGX MIL:DIA NAS:PRAH SHSE:603259 NYSE:WAT TSE:6869 NAS:SYNH SHSE:603658 SZSE:300676
Traded in other countries PKN.Germany 0KHE.UK
Address 940 Winter Street, Waltham, MA, USA, 02451
PerkinElmer provides instruments, consumables, and services to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes prenatal screening and infectious disease testing, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.

Ratios

Current vs industry vs history
PE Ratio (TTM) 42.05
PE Ratio ranked higher than
58.41% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
PKI: 42.05
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 5.3, Med: 28.63, Max: 3165
Current: 42.05
5.3
3165
Forward PE Ratio 23.09
Forward P/E ranked higher than
55.00% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
PKI: 23.09
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 42.05
PE without NRI ranked lower than
76.99% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
PKI: 42.05
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 11.52, Med: 29.19, Max: 2724
Current: 42.05
11.52
2724
Price-to-Owner-Earnings 39.92
Price-to-Owner-Earnings ranked higher than
65.79% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
PKI: 39.92
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 4.69, Med: 24.43, Max: 38590
Current: 39.92
4.69
38590
PB Ratio 3.95
PB Ratio ranked higher than
58.78% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
PKI: 3.95
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.88, Med: 2.25, Max: 4.22
Current: 3.95
0.88
4.22
PS Ratio 3.74
PS Ratio ranked lower than
51.30% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
PKI: 3.74
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.72, Med: 2.06, Max: 4.07
Current: 3.74
0.72
4.07
Price-to-Free-Cash-Flow 46.36
Price-to-Free-Cash-Flow ranked lower than
58.75% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
PKI: 46.36
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.76, Med: 22.62, Max: 93.47
Current: 46.36
7.76
93.47
Price-to-Operating-Cash-Flow 32.54
Price-to-Operating-Cash-Flow ranked lower than
65.98% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
PKI: 32.54
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 6.28, Med: 19.41, Max: 42.78
Current: 32.54
6.28
42.78
EV-to-EBIT 36.50
EV-to-EBIT ranked lower than
63.56% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
PKI: 36.5
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 10.5, Med: 29.15, Max: 59.2
Current: 36.5
10.5
59.2
EV-to-EBITDA 23.35
EV-to-EBITDA ranked lower than
56.06% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
PKI: 23.35
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 6.9, Med: 18.9, Max: 26.1
Current: 23.35
6.9
26.1
EV-to-Revenue 4.35
EV-to-Revenue ranked lower than
52.89% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
PKI: 4.35
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.9, Med: 2.4, Max: 4.9
Current: 4.35
0.9
4.9
PEG Ratio 3.71
PEG Ratio ranked lower than
58.33% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
PKI: 3.71
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 1.53, Med: 2.67, Max: 29.96
Current: 3.71
1.53
29.96
Shiller PE Ratio 52.08
Shiller PE Ratio ranked higher than
66.67% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
PKI: 52.08
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 14.4, Med: 30.97, Max: 56.55
Current: 52.08
14.4
56.55
Current Ratio 1.68
Current Ratio ranked lower than
81.60% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
PKI: 1.68
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.74, Med: 1.69, Max: 2.59
Current: 1.68
0.74
2.59
Quick Ratio 1.17
Quick Ratio ranked lower than
86.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
PKI: 1.17
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.54, Med: 1.24, Max: 2.09
Current: 1.17
0.54
2.09
Days Inventory 92.69
Days Inventory ranked lower than
52.94% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
PKI: 92.69
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 74.6, Med: 82.55, Max: 92.69
Current: 92.69
74.6
92.69
Days Sales Outstanding 81.84
Days Sales Outstanding ranked lower than
71.08% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
PKI: 81.84
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 71.98, Med: 78.47, Max: 89.32
Current: 81.84
71.98
89.32
Days Payable 56.13
Days Payable ranked higher than
55.08% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
PKI: 56.13
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 45.11, Med: 56.03, Max: 68.51
Current: 56.13
45.11
68.51

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 0.30
Trailing Dividend Yield ranked lower than
86.78% of 121 companies
in the Diagnostics & Research industry.
Industry Max: 10.16, Med: 0.81, Min: 0.07
PKI: 0.3
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.28, Med: 0.71, Max: 2.43
Current: 0.3
0.28
2.43
Dividend Payout Ratio 0.13
Dividend Payout Ratio ranked higher than
82.86% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 6.35, Med: 0.32, Min: 0.03
PKI: 0.13
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.13, Med: 0.22, Max: 28
Current: 0.13
0.13
28
Forward Dividend Yield % 0.30
Forward Dividend Yield ranked lower than
89.38% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 10.53, Med: 1.1, Min: 0.07
PKI: 0.3
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 0.30
Yield-on-Cost (5y) ranked lower than
90.14% of 142 companies
in the Diagnostics & Research industry.
Industry Max: 12, Med: 1.41, Min: 0.08
PKI: 0.3
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 0.28, Med: 0.71, Max: 2.43
Current: 0.3
0.28
2.43
3-Year Share Buyback Rate 0.20
3-Year Share Buyback Rate ranked higher than
92.78% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
PKI: 0.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -10.7, Med: 0.7, Max: 8.1
Current: 0.2
-10.7
8.1

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 2.12
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
58.67% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
PKI: 2.12
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.52, Med: 1.34, Max: 70.89
Current: 2.12
0.52
70.89
Price-to-DCF (Earnings Based) 1.60
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
100.00% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
PKI: 1.6
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.4, Med: 2.63, Max: 3.4
Current: 1.6
1.4
3.4
Price-to-Median-PS-Value 1.82
Price-to-Median-PS-Value ranked lower than
84.97% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
PKI: 1.82
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.15, Med: 0.74, Max: 1.98
Current: 1.82
0.15
1.98
Price-to-Peter-Lynch-Fair-Value 3.60
Price-to-Peter-Lynch-Fair-Value ranked lower than
86.67% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
PKI: 3.6
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.73, Med: 3.16, Max: 20.93
Current: 3.6
0.73
20.93
Earnings Yield (Joel Greenblatt) % 2.75
Earnings Yield (Greenblatt) ranked higher than
71.70% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
PKI: 2.75
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 1.7, Med: 3.4, Max: 9.5
Current: 2.75
1.7
9.5
Forward Rate of Return (Yacktman) % 14.00
Forward Rate of Return ranked higher than
70.00% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
PKI: 14
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -3.9, Med: 13, Max: 19.3
Current: 14
-3.9
19.3

More Statistics

Revenue (TTM) (Mil) $ 2,782.76
EPS (TTM) $ 2.22
Beta 1.47
Volatility % 31.61
52-Week Range $ 71.31 - 103
Shares Outstanding (Mil) 110.6

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N